We are comparing Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) and BioTime Inc. (NYSEAMERICAN:BTX) on their analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership. They both are Biotechnology companies, competing one another.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Ampio Pharmaceuticals Inc.||N/A||0.00||33.99M||-0.23||0.00|
Demonstrates Ampio Pharmaceuticals Inc. and BioTime Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 shows Ampio Pharmaceuticals Inc. and BioTime Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Ampio Pharmaceuticals Inc.||0.00%||-489.2%||381%|
Volatility & Risk
A 1.34 beta means Ampio Pharmaceuticals Inc.’s volatility is 34.00% more than Standard & Poor’s 500’s volatility. BioTime Inc.’s 200.00% more volatile than Standard & Poor’s 500 volatility due to the stock’s 3 beta.
The Current Ratio of Ampio Pharmaceuticals Inc. is 5.3 while its Quick Ratio stands at 5.3. The Current Ratio of rival BioTime Inc. is 8.2 and its Quick Ratio is has 8.2. BioTime Inc. is better equipped to clear short and long-term obligations than Ampio Pharmaceuticals Inc.
Insider and Institutional Ownership
Ampio Pharmaceuticals Inc. and BioTime Inc. has shares owned by institutional investors as follows: 24.5% and 45.1%. Insiders owned roughly 0.5% of Ampio Pharmaceuticals Inc.’s shares. Competitively, BioTime Inc. has 0.8% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Ampio Pharmaceuticals Inc.||5.89%||36.92%||8.61%||8.68%||-68.31%||73.4%|
For the past year Ampio Pharmaceuticals Inc. was more bullish than BioTime Inc.
On 5 of the 9 factors Ampio Pharmaceuticals Inc. beats BioTime Inc.
Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. Its product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor (BDNF) directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. The company also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer. In addition, it offers liquid biopsy tests for diagnosis of cancer; bone grafting products to treat orthopedic disorders; and mobile health software products. Further, it markets GeneCards, a human gene database; LifeMap Discovery, a database of embryonic development, stem cell research, and regenerative medicine; MalaCards, a human disease database; VarElect, an application for prioritizing gene variants; and GeneAnalytics, a novel gene set analysis tool. Additionally, the company develops and markets Hextend, a blood plasma volume expander used for the treatment of hypovolemia. BioTime, Inc. was founded in 1990 and is based in Alameda, California.